Funding round
Verdiva Bio Growth
Reported as "Growth Equity"
Verdiva Bio, which works in cardiometabolic disorder therapeutics development in Guildford, raised $457M in a Growth round announced on 19 Sep 2025, led by Forbion and General Atlantic. 7 firms took part. It is Verdiva Bio's second venture round on record; the one before was a Series A in Jan 2025.
$457M
Amount raised
337,150,000 GBP converted
Not disclosed
Post-money valuation
7
Investors
2 leads
Valuation
What this round says about the price
Verdiva Bio did not disclose a valuation in this round; its last disclosed one was $2.50B at the Series A (Jan 2025). It came 8 months after Verdiva Bio's Series A. It is 53% of the $868M Verdiva Bio has raised in the venture rounds on record. No later venture round is on record for Verdiva Bio.
Verdiva Bio's funding rounds
Verdiva Bio has 2 venture rounds on record. This one is highlighted.
- Series A 9 Jan 2025, led by Forbion and General Atlantic $411M$2.50B post-money
- Growth this round 19 Sep 2025, led by Forbion and General Atlantic $457M
Investors
Who put money in
Forbion and General Atlantic led the round with 5 other firms.
Lead investors
- backs 58 venture-backed companies new investor
- General Atlantic backs 134 venture-backed companies new investor
Also in the round
- backs 109 venture-backed companies new investor
- backs 93 venture-backed companies new investor
- Logos Capital new investor
- Lilly Asia Ventures new investor
- LYFE Capital new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development.
- Product development
Comparable rounds
How it compares
32 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $57M, and this round was 8.1 times the median. The closest in time, other companies' Growth rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 1 Sep 2025 | $100M | not disclosed | not named |
| Pharmaceutical Products | 18 Aug 2025 | $46M | not disclosed | Mellby Gård |
| Pharmaceutical Products | 21 Oct 2025 | $25M | not disclosed | not named |
| Pharmaceutical Products | 16 Oct 2025 | undisclosed | not disclosed | 1315 Capital |
| Pharmaceutical Products | 17 Nov 2025 | $31M | not disclosed | not named |
| Pharmaceutical Products | 15 Nov 2025 | undisclosed | not disclosed | not named |
| Pharmaceutical Products | 30 Jun 2025 | $252M | not disclosed | Coller Capital |
| Pharmaceutical Products | 4 Dec 2025 | $53M | not disclosed | LAV and ARCH Venture Partners |
Sources
Where this comes from
Reported by 6 sources.
Questions
Frequently asked
How much did Verdiva Bio raise in its Growth round?
Verdiva Bio raised $457M in its Growth round, announced in Sep 2025.
Who led Verdiva Bio's Growth round?
Forbion and General Atlantic led it, with RA Capital, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital.
What was Verdiva Bio's valuation at the Growth round?
It was not disclosed; its last disclosed one was $2.50B at the Series A (Jan 2025).
How does it compare with other Growth rounds in Pharmaceutical Products?
32 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $57M, and this round was 8.1 times the median.